Company Filing History:
Years Active: 2019-2023
Title: Innovations and Contributions of Hans-Lothar Arth
Introduction
Hans-Lothar Arth is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of technology and pharmaceuticals, holding a total of 3 patents. His work focuses on innovative solutions that address complex challenges in various domains.
Latest Patents
One of his latest patents is titled "Visualized Virtual Agent." This invention relates to a visualized virtual agent designed to provide a visual response to users. The agent is capable of delivering an artificial physiological color change response based on user-specific parameters, which include activity and physio-psychological data. The technology utilizes sensors to acquire user-specific data, enabling the agent to respond dynamically to changes in the user's condition.
Another significant patent is "Antisense-Oligonucleotides as Inhibitors of TGF-R Signaling." This invention involves antisense-oligonucleotides that are at least 10 nucleotides long, with a minimum of two nucleotides being locked nucleic acids (LNAs). These oligonucleotides serve as inhibitors of TGF-R signaling and are intended for use in pharmaceutical compositions aimed at treating neurological, neurodegenerative, fibrotic, and hyperproliferative diseases.
Career Highlights
Throughout his career, Hans-Lothar Arth has worked with various companies, including Neurovision Pharma GmbH and Mymeleon AG. His experience in these organizations has contributed to his expertise in developing innovative solutions in the pharmaceutical and technology sectors.
Collaborations
Hans-Lothar Arth has collaborated with notable colleagues such as Markus Hossbach and Monika Krampert. These partnerships have further enhanced his research and development efforts, leading to impactful inventions.
Conclusion
Hans-Lothar Arth's contributions to innovation and technology are evident through his patents and collaborations. His work continues to influence advancements in both the virtual agent and pharmaceutical fields.